What is EXUMA Biotech?
Founded in 2015, EXUMA Biotech Corp. is a private corporation dedicated to biotechnology research. The company focuses on developing novel therapeutics, leveraging advanced platforms to target complex diseases. Its operations are centered in West Palm Beach, Florida, positioning it within a growing hub for life sciences innovation. The company's commitment to research and development is evident in its pursuit of innovative solutions within the biotechnology landscape.
How much funding has EXUMA Biotech raised?
EXUMA Biotech has raised a total of $97M across 2 funding rounds:
Series A
$37M
Series B
$60M
Series A (2017): $37M with participation from BioAtla, F1 Bioventures, SINOBIOWAY GROUP, and SunTerra Capital
Series B (2021): $60M led by F1 BioVentures, MSD Partners, and Americo
Key Investors in EXUMA Biotech
BioAtla
BioAtla is a San Diego biotech company specializing in novel monoclonal antibody and cell-based therapeutics, utilizing proprietary platforms for targeted cancer treatment and improved manufacturability.
F1 Bioventures
F1 Bioventures LLC operates within the Research & Development industry, focusing on early-stage investments in the life sciences sector.
SINOBIOWAY GROUP
SINOBIOWAY GROUP is a significant entity in the biotechnology and pharmaceutical landscape, likely involved in strategic investments and development within the sector.
What's next for EXUMA Biotech?
With substantial backing, EXUMA Biotech is poised for accelerated development and expansion. The recent major strategic investment suggests a focus on scaling operations, advancing its research pipeline, and potentially forging new partnerships. This capital infusion will likely enable the company to move key projects through clinical trials and towards commercialization, solidifying its position in the competitive biotech market. Future endeavors may include further platform enhancements and strategic collaborations to maximize therapeutic impact.
See full EXUMA Biotech company page
